CR20160508A - Un profármaco de 1,1´-(1,6-dioxo-1,6-hexanodiilo)bis-d-prolina - Google Patents
Un profármaco de 1,1´-(1,6-dioxo-1,6-hexanodiilo)bis-d-prolinaInfo
- Publication number
- CR20160508A CR20160508A CR20160508A CR20160508A CR20160508A CR 20160508 A CR20160508 A CR 20160508A CR 20160508 A CR20160508 A CR 20160508A CR 20160508 A CR20160508 A CR 20160508A CR 20160508 A CR20160508 A CR 20160508A
- Authority
- CR
- Costa Rica
- Prior art keywords
- bis
- propharm
- hexanodyl
- prolina
- dioxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al compuesto 1,1'-adipoilbis(pirrolidina-2-carboxilato) de (2R,2'R)-Bis(((((tetrahidro-2H-piran-4-il)oxi)carbonil)oxi)metilo), composiciones famacéuticas que comprenden el mismo y el uso del mismo para el tratamiento de enfermedades o trastornos en los que la disminución del componente P del amiloide del suero (SAP por sus siglas en inglés) 2 sería beneficioso, incluido la amiloidosis, enfermedad de Alzheimer, diabetes mellitus tipo 2 y osteoartritis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1407506.3A GB201407506D0 (en) | 2014-04-29 | 2014-04-29 | Novel compound |
| PCT/EP2015/058998 WO2015165833A1 (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160508A true CR20160508A (es) | 2017-03-10 |
Family
ID=50972033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160508A CR20160508A (es) | 2014-04-29 | 2015-04-27 | Un profármaco de 1,1´-(1,6-dioxo-1,6-hexanodiilo)bis-d-prolina |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9701668B2 (es) |
| EP (1) | EP3137457B1 (es) |
| JP (1) | JP6445046B2 (es) |
| KR (1) | KR20160145617A (es) |
| CN (1) | CN106459016B (es) |
| AR (1) | AR100204A1 (es) |
| AU (1) | AU2015252184B2 (es) |
| BR (1) | BR112016025129A2 (es) |
| CA (1) | CA2947060C (es) |
| CL (1) | CL2016002721A1 (es) |
| CR (1) | CR20160508A (es) |
| DO (1) | DOP2016000292A (es) |
| EA (1) | EA032129B1 (es) |
| ES (1) | ES2731253T3 (es) |
| GB (1) | GB201407506D0 (es) |
| IL (2) | IL248249A0 (es) |
| MA (1) | MA39406B1 (es) |
| MX (1) | MX2016014246A (es) |
| MY (1) | MY191088A (es) |
| PE (1) | PE20161558A1 (es) |
| PH (1) | PH12016502006B1 (es) |
| SG (1) | SG11201608371RA (es) |
| TW (1) | TWI676624B (es) |
| UA (1) | UA119871C2 (es) |
| UY (1) | UY36098A (es) |
| WO (1) | WO2015165833A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2182203T3 (es) | 1997-10-31 | 2003-03-01 | Hoffmann La Roche | Derivados de d-prolina. |
| US6903129B2 (en) * | 2001-12-14 | 2005-06-07 | Hoffman-La Roche Inc. | D-proline prodrugs |
| CA2528065A1 (en) | 2003-06-05 | 2004-12-16 | Pfizer Products Inc. | Beta-lactamase inhibitor prodrug |
| GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| AU2006234532A1 (en) | 2005-04-12 | 2006-10-19 | Meiji Seika Kaisha, Ltd. | 2-Thioethenyl carbapenem derivative |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
-
2014
- 2014-04-29 GB GBGB1407506.3A patent/GB201407506D0/en not_active Ceased
-
2015
- 2015-04-27 MX MX2016014246A patent/MX2016014246A/es active IP Right Grant
- 2015-04-27 EP EP15720312.6A patent/EP3137457B1/en active Active
- 2015-04-27 PE PE2016001934A patent/PE20161558A1/es unknown
- 2015-04-27 AU AU2015252184A patent/AU2015252184B2/en active Active
- 2015-04-27 UY UY0001036098A patent/UY36098A/es not_active Application Discontinuation
- 2015-04-27 AR ARP150101262A patent/AR100204A1/es active IP Right Grant
- 2015-04-27 CN CN201580023347.0A patent/CN106459016B/zh not_active Expired - Fee Related
- 2015-04-27 EA EA201692185A patent/EA032129B1/ru not_active IP Right Cessation
- 2015-04-27 UA UAA201612105A patent/UA119871C2/uk unknown
- 2015-04-27 SG SG11201608371RA patent/SG11201608371RA/en unknown
- 2015-04-27 MA MA39406A patent/MA39406B1/fr unknown
- 2015-04-27 US US14/787,608 patent/US9701668B2/en active Active
- 2015-04-27 ES ES15720312T patent/ES2731253T3/es active Active
- 2015-04-27 TW TW104113338A patent/TWI676624B/zh active
- 2015-04-27 JP JP2016565212A patent/JP6445046B2/ja active Active
- 2015-04-27 CR CR20160508A patent/CR20160508A/es unknown
- 2015-04-27 KR KR1020167029703A patent/KR20160145617A/ko not_active Application Discontinuation
- 2015-04-27 CA CA2947060A patent/CA2947060C/en active Active
- 2015-04-27 WO PCT/EP2015/058998 patent/WO2015165833A1/en active Application Filing
- 2015-04-27 MY MYPI2016703952A patent/MY191088A/en unknown
- 2015-04-27 BR BR112016025129A patent/BR112016025129A2/pt not_active Application Discontinuation
-
2016
- 2016-10-09 IL IL248249A patent/IL248249A0/en active IP Right Grant
- 2016-10-10 PH PH12016502006A patent/PH12016502006B1/en unknown
- 2016-10-26 CL CL2016002721A patent/CL2016002721A1/es unknown
- 2016-10-28 DO DO2016000292A patent/DOP2016000292A/es unknown
-
2017
- 2017-06-01 US US15/610,984 patent/US9873686B2/en active Active
- 2017-12-11 US US15/837,297 patent/US10597385B2/en active Active
-
2020
- 2020-12-01 IL IL279120A patent/IL279120A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012002896A1 (es) | Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva. | |
| BR112017008198A2 (pt) | pró-fármacos de carbidopa e l-dopa e métodos de uso | |
| CR20110509A (es) | Composicion farmaceutica | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| CO6382089A2 (es) | Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
| CO2017004994A2 (es) | Análogos de urea unidos sustituidos como moduladores de sirtuina | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| DOP2016000292A (es) | Un profármaco de 1,1'-(1,6-dioxo-1,6-hexanodiilo)bis-d-prolina | |
| CL2017001843A1 (es) | Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. | |
| UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| CL2017002326A1 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| UY36347A (es) | Compuestos y su uso como inhibidores de bace | |
| CO2019004131A2 (es) | Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma | |
| BR112016016098A2 (pt) | Compostos orgânicos | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| CL2016001054A1 (es) | Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma |